Journals / Experimed / 2023 / Cilt: 13 Sayı: 1

Histopathological and Serum Biomarkers Analyses in MRONJ due to Periodontal Disease in Rats: Comparison of Zoledronic Acid and Denosumab

Journal
Experimed
Pages
8–14
Publication Date
2023-05-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Since the long-term use of bisphosphonates can cause osteonecrosis in the jaw bones, it should not be overlooked that this can also be caused by chronic inflammatory conditions such as periodontal disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate the bisphosphonate and denosumab effects in medication-related osteonecrosis of the jaws (MRONJ) caused by periodontal disease with analyses of serum biomarkers and histopathology.
📊
Key Findings & Data:The rats were divided into a zoledronic acid group (ZG) (n=12), a denosumab group (DG) (n=12), a saline group (SG) (n=10), and a control group (CG) (n=6).
💡
Conclusion & Impact:Conclusion: Since the long-term use of bisphosphonates can cause osteonecrosis in the jaw bones, it should not be overlooked that this can also be caused by chronic inflammatory conditions such as periodontal disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Bisphosphonates · denosumab · osteonecrosis

Abstract

Objective: This study aimed to investigate the bisphosphonate and denosumab effects in medication-related osteonecrosis of the jaws (MRONJ) caused by periodontal disease with analyses of serum biomarkers and histopathology. Materials and Methods: Forty Copenhagen rats were used in the study. A ligature wire was wrapped around the first molars to induce periodontal disease. The rats were divided into a zoledronic acid group (ZG) (n=12), a denosumab group (DG) (n=12), a saline group (SG) (n=10), and a control group (CG) (n=6). Prostate cancer was induced by injections for ZG, DG, and SG following the ligature application, and injections were repeated on the 14th and 21st days. While periodontal disease was evaluated clinically with gingival edema, swelling and redness, serum osteocalcin, osteopontin, parathormone and receptor activator of nuclear factor-kappa B ligand (RANKL) levels were evaluated using the LUMINEX technique. The Mann-Whitney U test was used for the comparison of parameters between groups (p<0.05). Results: The osteocalcin levels were increased in CG, RANKL levels were decreased in DG, osteopontin levels were increased in ZG, and parathormone levels were increased in both ZG and CG. Conclusion: Since the long-term use of bisphosphonates can cause osteonecrosis in the jaw bones, it should not be overlooked that this can also be caused by chronic inflammatory conditions such as periodontal disease.

🔖

Cite This Article

ÖZBEK, C., KOCA-ÜNSAL, R. B., TEKKEŞİN, M. S., ÇELİK, F., ERGEN, H. A., ZEYBEK, Ü., KAYHAN, K. B., ÜNÜR, M. (2023). Histopathological and Serum Biomarkers Analyses in MRONJ due to Periodontal Disease in Rats: Comparison of Zoledronic Acid and Denosumab. Experimed, Cilt: 13 Sayı: 1, 8–14. https://ajindex.com/articles/936349

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 2017
  2. google scholar 2. Listgarten MA. Pathogenesis of periodontitis. J Clin Periodontol 1986
  3. [CrossRef] google scholar 3. Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RJ, Migliorati CA et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 2017
  4. [CrossRef] google scholar 4. Kmetec A and Hajdinjak T. Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid. Radiol Oncol 2013
  5. [CrossRef] google scholar 5. Wu S, Dahut WL and Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007
  6. [CrossRef] google scholar 6. Mehrotra B. Bisphosphonates--role in cancer therapies. J Oral Maxillofac Surg 2009
  7. [CrossRef] google scholar 7. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008
  8. 103245. [CrossRef] google scholar 8. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995
  9. [CrossRef] google scholar 9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003
  10. [CrossRef] google scholar 10. Rustemeyer J and Bremerich A. Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 2010
  11. [CrossRef] google scholar 11. Sivolella S, Lumachi F, Stellini E, Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res 2013
  12. google scholar 12. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 2014
  13. [CrossRef] google scholar 13. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 2